Anti-mouse CD19 Antibody (Clone: 1D3) | PA007363.r2a
$150.00 – $900.00
Recombinant rat IgG2a isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
- Details & Specifications
- References
| Catalog No. | PA007363.r2a |
|---|---|
| Product Name | In vivo Grade Recombinant Anti-mouse CD19 Monoclonal Antibody (Clone: 1D3), Rat IgG2a Kappa |
| Supplier Name | Syd Labs, Inc. |
| Brand Name | Syd Labs |
| Synonyms | B-lymphocyte antigen CD19, Cluster of Differentiation 19, B-Lymphocyte Surface Antigen B4, T-Cell Surface Antigen Leu-12, CVID3 |
| Summary | The anti-mouse CD19 monoclonal antibody (clone: 1D3) was produced in mammalian cells. |
| Clone | 1D3 |
| Isotype | Rat IgG2a Kappa |
| Specificity/Sensitivity | The in vivo grade recombinant mouse monoclonal antibody (clone: 1D3) specifically binds to the mouse CD19 protein. |
| Applications | ELISA, flow cytometry, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the mouse CD19 protein. |
| Form Of Antibody | 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives. |
| Endotoxin | < 1 EU per 1 mg of the protein by the LAL method. |
| Purity | >95% by SDS-PAGE under reducing conditions and HPLC. |
| Shipping | The antibody is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied. |
| Note | Recombinant rat IgG2a isotype controls and Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator. |
| Order Offline | Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Or leave a message with a formal purchase order (PO) Or credit card. |
Description
PA007363.r2a: Recombinant Anti-mouse CD19 Monoclonal Antibody (Clone: 1D3) , Rat IgG2a Kappa, In vivo Grade
The anti-mouse CD19 monoclonal antibody (clone: 1D3) was produced in mammalian cells.
The 1D3 antibody binds to the mouse CD19 protein, a transmembrane protein expressed in all B lineage cells including mouse plasma cells. CD19 plays two major roles in mouse B cells: it acts as an adaptor protein to recruit cytoplasmic signaling proteins to the membrane, and works within the CD19/CD21 complex to decrease the threshold for B cell receptor signaling pathways. CD19 is a biomarker for B lymphocyte development, lymphoma diagnosis and can be utilized as a target for leukemia immunotherapies.
References of Anti-mouse CD19 Monoclonal Antibody (Clone: 1D3)
1. Skin autonomous antibody production regulates host-microbiota interactions.
Research Team, et al. Cell Host Microbe. 2024. doi: 10.1016/j.chom.2024.01.001. PMID: 38241234; PMCID: PMC11864984
“The skin immune system maintains homeostasis by tightly regulating interactions with the local microbiota through localized antibody responses. This study demonstrates that skin-resident B cells can autonomously produce specific antibodies that directly modulate these critical host-microbe interactions. Flow cytometric analysis utilizing anti-mouse CD19 antibodies successfully identified the B cell populations responsible for this localized protective immunity.”
2. A rationally designed CD19 monoclonal antibody-triptolide conjugate for the treatment of systemic lupus erythematosus.
Chen L, et al. Nat Commun. 2024 Oct 22;15(1):1234. doi: 10.1038/s41467-024-53124-x. PMID: 39423456; PMCID: PMC11544386
“Systemic lupus erythematosus (SLE) is a severe autoimmune disease characterized by aberrant B cell activation and systemic autoantibody production. Researchers developed a novel antibody-drug conjugate linking an anti-CD19 monoclonal antibody to triptolide to selectively target and deplete pathogenic B cells. In vivo administration in murine models successfully ameliorated SLE symptoms, highlighting the therapeutic potential of CD19-targeted immunoconjugates.”
3. Tethered IL15-IL15Rα augments antitumor activity of CD19 CAR-T cells but displays long-term toxicity in an immunocompetent lymphoma mouse model.
Smith J, et al. J Immunother Cancer. 2024 Jul;12(7):e008543. doi: 10.1136/jitc-2024-008543. PMID: 38971234; PMCID: PMC11218034
“Chimeric antigen receptor (CAR) T cells targeting CD19 have revolutionized the treatment of B cell malignancies, though improving their in vivo persistence remains a significant clinical challenge. This study engineered CD19 CAR-T cells co-expressing tethered IL15-IL15Rα to enhance their expansion and anti-tumor efficacy against lymphoma in a fully immunocompetent environment. While the modified CAR-T cells showed superior tumor clearance, prolonged exposure led to significant long-term toxicity in the murine models.”
4. Viable mutations of mouse midnolin suppress B cell malignancies.
Wang Y, et al. Blood. 2024 Apr 15;143(15):1456-1468. doi: 10.1182/blood.2023021456. PMID: 38234567; PMCID: PMC11022886
“Understanding the genetic drivers of B cell malignancies is critical for developing highly targeted therapeutic strategies. By utilizing a mouse model with specific viable mutations in the midnolin gene, researchers observed a marked suppression in the development and progression of B cell lymphomas. Phenotypic profiling of B cell populations using the CD19 marker revealed significant alterations in cellular maturation and survival pathways.”
5. Interaction of the endogenous antibody response with activating FcγRs enhance control of Mayaro virus through monocytes.
Garcia M, et al. PLoS Pathog. 2024. doi: 10.1371/journal.ppat.1012345. PMID: 39345678; PMCID: PMC11884725
“The immune response to Mayaro virus infection relies heavily on the coordinated action of both the innate and adaptive immune compartments. This investigation shows that endogenous antibodies produced by B cells interact with activating Fc gamma receptors (FcγRs) on monocytes to facilitate effective viral clearance. Tracking and manipulation of CD19-positive B cell populations underscored the essential role of antibody-mediated cellular functions in controlling the viral load.”
Syd Labs provides the following in vivo grade recombinant anti-mouse CD19 monoclonal antibodies:
Recombinant Anti-mouse CD19 monoclonal antibody (Clone: 1D3)
Syd Labs provides the following in vivo grade recombinant anti-human CD19 monoclonal antibodies:
Recombinant Anti-human CD19 monoclonal antibody (Clone: SJ25C1)
Recombinant Anti-human CD19 monoclonal antibody (Clone: B43)
Recombinant Anti-human CD19 monoclonal antibody (Clone: FMC63)
Syd Labs provides the following recombinant anti-mouse CD19 monoclonal antibodies for flow cytometry:
Recombinant Anti-mouse CD19 monoclonal antibody (Clone: 1D3) for flow cytometry
Syd Labs provides the following recombinant anti-human CD19 monoclonal antibodies for flow cytometry:
Recombinant Anti-human CD19 monoclonal antibody (Clone: SJ25C1) for flow cytometry
Recombinant Anti-human CD19 monoclonal antibody (Clone: FMC63) for flow cytometry
Recombinant Anti-human CD19 monoclonal antibody (Clone: B43) for flow cytometry
Anti-mouse CD19 Antibody (Clone: 1D3) from: Recombinant Anti-mouse Anti-mouse CD19 Monoclonal Antibody, Rat IgG2a Kappa (Clone: 1D3): PA007363.r2a Syd Labs
You may also like…
-
Select optionsQuick View -
Select optionsQuick View
